文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症中的表观遗传调控。

Epigenetic regulation in cancer.

作者信息

Gu Minzhi, Ren Bo, Fang Yuan, Ren Jie, Liu Xiaohong, Wang Xing, Zhou Feihan, Xiao Ruiling, Luo Xiyuan, You Lei, Zhao Yupei

机构信息

Department of General Surgery Peking Union Medical College Hospital Peking Union Medical College Chinese Academy of Medical Sciences Beijing P. R. China.

Key Laboratory of Research in Pancreatic Tumor Chinese Academy of Medical Sciences Beijing P. R. China.

出版信息

MedComm (2020). 2024 Feb 19;5(2):e495. doi: 10.1002/mco2.495. eCollection 2024 Feb.


DOI:10.1002/mco2.495
PMID:38374872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10876210/
Abstract

Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations that impact genome's structure and function. Genetic mutations, which directly disrupt the DNA sequence, are complemented by epigenetic modifications that modulate gene expression, thereby facilitating the acquisition of malignant characteristics. Principals among these epigenetic changes are shifts in DNA methylation and histone mark patterns, which promote tumor development and metastasis. Notably, the reversible nature of epigenetic alterations, as opposed to the permanence of genetic changes, positions the epigenetic machinery as a prime target in the discovery of novel therapeutics. Our review delves into the complexities of epigenetic regulation, exploring its profound effects on tumor initiation, metastatic behavior, metabolic pathways, and the tumor microenvironment. We place a particular emphasis on the dysregulation at each level of epigenetic modulation, including but not limited to, the aberrations in enzymes responsible for DNA methylation and histone modification, subunit loss or fusions in chromatin remodeling complexes, and the disturbances in higher-order chromatin structure. Finally, we also evaluate therapeutic approaches that leverage the growing understanding of chromatin dysregulation, offering new avenues for cancer treatment.

摘要

表观遗传修饰被定义为基因活性的可遗传变化,这些变化不涉及潜在DNA序列的改变。致癌过程是由影响基因组结构和功能的改变积累所驱动的。直接破坏DNA序列的基因突变,辅以调节基因表达的表观遗传修饰,从而促进恶性特征的获得。这些表观遗传变化的主要方面是DNA甲基化和组蛋白标记模式的改变,它们促进肿瘤的发展和转移。值得注意的是,与基因变化的永久性相反,表观遗传改变的可逆性使表观遗传机制成为发现新型治疗方法的主要靶点。我们的综述深入探讨了表观遗传调控的复杂性,探索其对肿瘤发生、转移行为、代谢途径和肿瘤微环境的深远影响。我们特别强调表观遗传调控各层面的失调,包括但不限于负责DNA甲基化和组蛋白修饰的酶的异常、染色质重塑复合物中的亚基缺失或融合,以及高阶染色质结构的紊乱。最后,我们还评估了利用对染色质失调日益深入的理解的治疗方法,为癌症治疗提供了新途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/28647f822fad/MCO2-5-e495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/09c5d052adf5/MCO2-5-e495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/28647f822fad/MCO2-5-e495-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/09c5d052adf5/MCO2-5-e495-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b7/10876210/ba0d55dd3df4/MCO2-5-e495-g004.jpg

相似文献

[1]
Epigenetic regulation in cancer.

MedComm (2020). 2024-2-19

[2]
Epigenomics in stress tolerance of plants under the climate change.

Mol Biol Rep. 2023-7

[3]
Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review.

Cancers (Basel). 2023-11-27

[4]
Cancer epigenetics in clinical practice.

CA Cancer J Clin. 2023

[5]
MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer.

Cancers (Basel). 2019-6-27

[6]
Analytical and therapeutic profiles of DNA methylation alterations in cancer; an overview of changes in chromatin arrangement and alterations in histone surfaces.

Horm Mol Biol Clin Investig. 2023-9-1

[7]
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.

Cancer Commun (Lond). 2022-11

[8]
The epigenomics of sarcoma.

Nat Rev Cancer. 2020-8-11

[9]
Targeting Chromatin Remodeling for Cancer Therapy.

Curr Mol Pharmacol. 2019

[10]
Effect of non-enzymatic glycosylation in the epigenetics of cancer.

Semin Cancer Biol. 2022-8

引用本文的文献

[1]
CRISPR/dCas9-TET1-mediated epigenetic editing reactivates miR-200c in breast cancer cells.

Sci Rep. 2025-8-28

[2]
Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies.

Pharmaceuticals (Basel). 2025-7-31

[3]
Deciphering Medulloblastoma: Epigenetic and Metabolic Changes Driving Tumorigenesis and Treatment Outcomes.

Biomedicines. 2025-8-4

[4]
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies.

Med Oncol. 2025-7-21

[5]
Current Bioinformatics Tools in Precision Oncology.

MedComm (2020). 2025-7-9

[6]
The role of abnormal epigenetic regulation of small GTPases in glioma (Review).

Int J Oncol. 2025-8

[7]
Valproic acid exposure alters histone deacetylase mRNA expression profile in oral cancer and premalignant cell lines.

Biomed Rep. 2025-6-11

[8]
Epigenetic regulators in cancer therapy and progression.

NPJ Precis Oncol. 2025-6-28

[9]
Clinical Model Based on DR3 Promoter Methylation for Predicting Short-Term Mortality in Patients with Acute-on-Chronic Hepatitis B Liver Failure.

Int J Gen Med. 2025-6-19

[10]
Case Report: FAP fibroblasts and SPP1 macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis.

Front Immunol. 2025-5-16

本文引用的文献

[1]
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs.

Cell. 2023-6-22

[2]
Metastasis.

Cell. 2023-4-13

[3]
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.

Clin Cancer Res. 2023-6-1

[4]
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.

Cancer Cell. 2023-3-13

[5]
Epigenetics as a mediator of plasticity in cancer.

Science. 2023-2-10

[6]
The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.

J Exp Clin Cancer Res. 2023-2-9

[7]
Acetyl-CoA metabolism in cancer.

Nat Rev Cancer. 2023-3

[8]
DNA Methylation-Mediated Overexpression of in -Induced Gastric Cancer: In Silico- and In Vitro-Based Identification of a Potential Biomarker for Carcinogenesis.

Int J Mol Sci. 2023-1-2

[9]
Cancer epigenetics in clinical practice.

CA Cancer J Clin. 2023

[10]
EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.

Nat Commun. 2022-11-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索